The maker of Wegovy and Ozempic, Novo Nordisk, has predicted a sharp drop in revenues this year owing to what its boss described as a painful push by Donald Trump to lower US weight-loss drug prices, rising competition, and the loss of important patent protections
TSH (thyroid) and HbA1c (blood sugar) on file
Comment GLP1ARTICLE and well send you our evidence-based article on Ozempic and GLP-1 medications right to your inbox
What practical steps could the UK or EU Patent Offices take right now to review these massive patent portfolios critically, ensuring that strategic filing doesn't unduly restrict access for a drug class with such profound public health implications
GST-HDAC1 pull-down Approximately 1 g of GST or GST-HDAC1 protein bound to Glutathione Sepharose 4B beads was incubated with 1 g of purified His-C16orf87 protein in binding buffer (50 mM TrisHCl, pH 7.5, 100 mM NaCl, 10% glycerol, 0.5% NP-40, and 10 mM MgCl)
Confirm the medication matches what you use at home